JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Shun Yamamoto; Ken Kato

doi:10.1016/j.ccell.2022.02.009

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Cancer Cell. 2022 Mar 14;40(3):238-240. doi: 10.1016/j.ccell.2022.02.009. Epub 2022 Mar 3.

Authors

Shun Yamamoto¹, Ken Kato²

Affiliations

¹ Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: [email protected].

PMID: 35245448
DOI: 10.1016/j.ccell.2022.02.009

Abstract

The phase III JUPITER-6 trial showed superior progression-free survival and overall survival for toripalimab plus chemotherapy, compared with chemotherapy alone, in previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors are key drugs for the first-line treatment of advanced esophageal squamous cell carcinoma.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drugs, Essential* / therapeutic use
Esophageal Neoplasms* / drug therapy
Esophageal Squamous Cell Carcinoma* / drug therapy
Esophageal Squamous Cell Carcinoma* / mortality
Humans
Immune Checkpoint Inhibitors / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Drugs, Essential
Immune Checkpoint Inhibitors
toripalimab